Candel Therapeutics Inc.

12/11/2024 | Press release | Distributed by Public on 12/11/2024 06:17

Candel Therapeutics Announces CAN 2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease Free Survival